Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 5.0 | 4.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 1.93 | 1.89 |
NAV | ₹426.54 | ₹39.37 |
Fund Started | 04 Jun 1999 | 25 Jun 2018 |
Fund Size | ₹3689.28 Cr | ₹5507.52 Cr |
Exit Load | Exit load of 0.50% if redeemed within 15 days | Exit load of 1% if redeemed within 15 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 19.31% | 21.93% |
3 Year | 29.09% | 29.75% |
5 Year | 24.17% | 25.03% |
1 Year
3 Year
5 Year
Equity | 96.09% | 96.99% |
Cash | 3.83% | 3.01% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 12.73% |
Divi's Laboratories Ltd. | 7.39% |
Max Healthcare Institute Ltd. | 6.40% |
Lonza Group Ag | 4.81% |
Cipla Ltd. | 4.77% |
Lupin Ltd. | 4.46% |
Mankind Pharma Ltd. | 3.75% |
Krishna Institute of Medical Sciences Ltd | 3.34% |
Fortis Healthcare Ltd. | 3.22% |
Acutaas Chemicals Ltd. | 3.19% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 12.66% |
Dr. Reddy's Laboratories Ltd. | 9.66% |
Divi's Laboratories Ltd. | 9.03% |
Cipla Ltd. | 7.85% |
Aurobindo Pharma Ltd. | 6.34% |
Alkem Laboratories Ltd. | 4.12% |
Zydus Lifesciences Ltd. | 4.01% |
Lupin Ltd. | 3.98% |
Gland Pharma Ltd. | 3.95% |
Syngene International Ltd. | 2.46% |
Name | Tanmaya Desai | Dharmesh Kakkad |
Start Date | 27 Jun 2011 | 23 Feb 2021 |
Name
Start Date
Description | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 04 Jun 1999 | 25 Jun 2018 |
Description
Launch Date